Abstract
The aim of this current study was to investigate the clinicopathologic features and prognostic significance of UbcH10 in pancreatic ductal adenocarcinoma (PDA). Real-time quantitative RT-PCR was employed to examine UbcH10 expression in 20 pairs of PDA and adjacent non-cancerous tissues. In addition, UbcH10 expression was analyzed by immunohistochemistry in 94 clinicopathologically characterized PDA cases. The correlation of UbcH10 expression with patients’ survival rate was assessed by Kaplan–Meier and Cox regression. Our results showed that the expression levels of UbcH10 mRNA and protein in PDA tissues were both significantly higher than those in non-cancerous tissues. Simultaneously, high expression of UbcH10 was significantly correlated with the clinical stage (p < 0.001), degree of histological differentiation (p < 0.001), and lymph node metastasis (p = 0.001). Moreover, high expression of UbcH10 was significantly associated with poor overall survival in PDA patients. In conclusion, UbcH10 might play a positive role in tumor development and could serve as an independent predictor of poor prognosis for PDA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Zali MR, Pourhoseingholi MA. Pancreatic cancer mortality and misclassification—bayesian analysis. Asian Pac J Cancer Prev. 2011;12:2271–4.
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–9. doi:10.1016/j.surg.2012.05.020.
Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22. doi:10.1002/jso.23192.
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003;63:4167–73.
Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007;43:2729–35.
Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2007;26:2136–40. doi:10.1038/sj.onc.1210010.
Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005;93:464–71. doi:10.1038/sj.bjc.6602721.
Lin J, Raoof DA, Wang Z, Lin MY, Thomas DG, Greenson JK, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 2006;8:1062–71.
Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, et al. UbcH10 expression in human lymphomas. Histopathology. 2009;54:731–40. doi:10.1111/j.1365-2559.2009.03296.x.
Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 2009;9:87.
Chen SM, Jiang CY, Wu JY, Liu B, Chen YJ, Hu CJ, et al. RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 2010;37:525–9.
Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011;30:2405–19. doi:10.1038/emboj.2011.154.
Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121:33–8. doi:10.1002/ijc.22605.
van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 2010;188:83–100. doi:10.1083/jcb.200906147.
Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004;23:6621–9. doi:10.1038/sj.onc.1207861.
Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med. 2008;12:1495–501. doi:10.1111/j.1582-4934.2008.00309.x.
Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28. doi:10.2353/ajpath.2009.080874.
Yang S. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–33. doi:10.1038/nrg2218.
Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008;123:1–7. doi:10.1002/ijc.23605.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Ze-Kun Zhao and Wen-Guang Wu contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Zhao, ZK., Wu, WG., Chen, L. et al. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis. Tumor Biol. 34, 1473–1477 (2013). https://doi.org/10.1007/s13277-013-0671-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-0671-9